Bioorganic and Medicinal Chemistry Letters p. 2635 - 2640 (1998)
Update date:2022-08-03
Topics:
Montana, John G.
Buckley, George M.
Cooper, Nicola
Dyke, Hazel J.
Gowers, Lewis
Gregory, Joanna P.
Hellewell, Paul G.
Kendall, Hannah J.
Lowe, Christopher
Maxey, Robert
Miotla, Jadwiga
Naylor, Robert J.
Runcie, Karen A.
Tuladhar, Bishwa
Warneck, Julie B. H.
A series of novel selective phosphodiesterase 4 (PDE4) inhibitors has been developed which displays activity both in vitro and in vivo. These compounds possess good selectivity for the catalytic site of PDE4 over the high affinity Rolipram binding site. In vivo studies demonstrate a reduced propensity to display the emetic side effects which are commonly observed with PDE4 inhibitors.
View MoreContact:86-21-34622192，13917187091，21-34622765
Address:No. 500 Caobao Road Shanghai P.R China
Shenyang Mole pharmaceutical Technology Development Co.,Ltd
Contact:+86-24-31204918/13889278616
Address:No.44, wanliutang road, shenhe District of Shenyang
Compro Shijiazhuang Fine Chemical Co., Ltd
Contact:0086-311-89689838
Address:Economic and Technological Development Zone of Shijiazhuang,Hebei
Shanghai Xinda Pharmaceuticals Co., Ltd.
Contact:86-21-33692333-8008
Address:999 Linxian Road, Jinshan Industrial Park, Shanghai, China
Contact:+86-571-86217390
Address:No.567 Dengcai Street,Sandun,Westlake District,Hangzhou310030,Zhejiang,China.
Doi:10.1021/jm301217c
(2012)Doi:10.1021/ic300872m
(2012)Doi:10.1021/jm301212u
(2012)Doi:10.1007/BF00901092
(1967)Doi:10.1039/c2ob26103k
(2012)Doi:10.1016/j.bmcl.2012.08.089
(2012)
